<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60343">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844635</url>
  </required_header>
  <id_info>
    <org_study_id>APBMT AAWG-01</org_study_id>
    <nct_id>NCT01844635</nct_id>
  </id_info>
  <brief_title>Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA</brief_title>
  <official_title>A Prospective Randomized Multicenter Study Comparing Different Dosages of Rabbit Antithymocyte Globulin (Thymoglobuline) in Patients With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nagoya University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the feasibility and effectiveness of
      immunosuppressive therapy (IST) using rabbit anti-thymocyte globulin (ATG) (Thymoglobuline,
      Genzyme) for patients with very severe aplastic anemia (VSAA) and severe aplastic anemia
      (SAA) as a primary therapy. The primary endpoint is the response rate (complete response
      (CR) + partial response (PR)) at day 180 after the start of IST. Secondary endpoints include
      evaluation of the presence and frequency of Epstein-Barr virus (EBV)-reactivation and
      EBV-associated lymphoproliferative disorder (EBV-LPD), Cytomegalovirus(CMV)-reactivation and
      CMV associated diseases, the response rate (CR+PR) on Day 360 after the start of IST,
      relapse rate and overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hematologic response (complete response (CR) or partial response (PR)) in patients with immunosuppressive therapy (IST) on day 180 after the start of IST.</measure>
    <time_frame>day 180 after the start of IST</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Acquired Aplastic Anemia.</condition>
  <arm_group>
    <arm_group_label>2.5 mg/kg/day of Thymoglobulin for 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg/kg/day of Thymoglobulin for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.5 mg/kg/day of Thymoglobulin for 5 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.5 mg/kg/day of Thymoglobulin for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>2.5 mg/kg/day of Thymoglobulin for 5 days</arm_group_label>
    <arm_group_label>3.5 mg/kg/day of Thymoglobulin for 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acquired aplastic anemia

          -  Age:  younger than 70 years old

          -  Severity: SAA, VSAA.

          -  Interval between diagnosis and registration &lt;6 months.

          -  Written informed consent from the caretakers and/or whenever possible consent from
             the patient.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seiji Kojima, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Nagoya University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seiji Kojima, MD., PhD.</last_name>
    <phone>+81-52-744-2294</phone>
    <email>kojimas@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hideki Muramatsu, MD., PhD.</last_name>
    <phone>+81-52-744^2294</phone>
    <email>hideki-muramatsu@med.nagoya-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seiji Kojima, MD., PhD.</last_name>
      <phone>+81-52-744-2294</phone>
      <email>kojimas@med.nagoya-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Hideki Muramatsu, MD., PhD.</last_name>
      <phone>+81-52-744-2294</phone>
      <email>hideki-muramatsu@med.nagoya-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Seiji Kojima, MD., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 29, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>Hideki Muramatsu</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
